English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/72304
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors

AuthorsSardinha, Ruth; Hernández, M. Teresa ; Fraile, Susana ; Tresserra, Francesc; Vidal, August; Gómez, Maria Carmén; Astudillo, Aurora; Hernández, Nieves; Saenz de Santamaría, Javier; Ordi, Jaume; Gonçalves, Luis; Ramos, Rafael; Balañá, Carmen; Álava, Enrique de
Issue Date7-Mar-2013
PublisherBioMed Central
CitationClinical Sarcoma Research 3(1): 3- (2013)
AbstractAbstract Background The systemic treatment of malignant endometrial stromal tumors (EST) is not well established. A few reports describe objective responses to imatinib, which suggest a novel therapeutic strategy for these tumors. Due to these facts, we aimed to perform a retrospective analysis of possible molecular targets of tyrosine kinase inhibitors (TKI) in EST: KIT, PDGFRA and EGFR. Methods 52 endometrial stromal sarcomas and 13 undifferentiated endometrial sarcomas were examined and reviewed. Mutational analysis were performed for exons 9, 11, 13, and 17 of the KIT gene, exons 12 and 18 of the PDGFRA gene and exons 18, 19, 20 and 21 of the EGFR gene. The incidence and distribution of the KIT, PDGFRA, and EGFR expression were examined by immunohistochemistry, and EGFR amplification was assessed by fluorescence in situ hybridization. Results No mutations in KIT, PDGFRA and EGFR genes were detected. Overexpression of KIT, PDGFRA, EGFR, was detected in 2 (3%), 23 (35.4%), 7 (10.8%) cases respectively, whereas amplification of EGFR gene was not found. Conclusions Absence of significant expression, amplification and activating mutations on these tyrosine kinase receptors suggest that it is unlikely that EST can benefit from therapies such as TKI on the systemic setting.
URIhttp://hdl.handle.net/10261/72304
Identifiershttp://dx.doi.org/10.1186/2045-3329-3-3
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
2045-3329-3-3.xml118,23 kBXMLView/Open
2045-3329-3-3.pdf1,25 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.